- Second-line camrelizumab plus apatinib showed potent antitumor activity in patients with extensive-stage small cell lung cancer (SCLC) with acceptable toxicity profile.
Why this matters
- Current standard in this setting has low response rate and short duration of response.
- The 3-parallel-cohort, phase 2 PASSION trial.
- 18 patients with extensive-stage SCLC were randomly assigned (1:1:1; stage 1) to receive intravenous camrelizumab every 2 weeks with oral apatinib either once daily (QD), 5 days on/2 days off, or 7 days on/7 days off.
- The QD cohort was expanded to 47 patients in stage 2.
- Funding: Jiangsu Hengrui Medicine Co. Ltd.
- The overall response rate (ORR) was 34.0% in the QD cohort and 33.3% in the other 2 cohorts.
- In the QD cohort:
- ORR: 34.0%.
- OS: 8.4 months.
- PFS: 3.6 months.
- In chemo-sensitive and chemo-resistant patients (disease relapse in ≥90 and ˂90 days after platinum-based chemotherapy, respectively), no difference was seen in:
- ORR (37.5% vs 32.3%);
- median PFS (3.6 vs 2.7 months); and
- median OS (9.6 vs 8.0 months).
- Grade ≥3 treatment-related adverse event rate was 72.9%; most common were hypertension (25.4%), hand-foot syndrome (13.6%), and decreased platelet count (13.6%).
- Toxicity-related discontinuation rate: 8.4%.
- No treatment-related death was reported.
- Open-label, no comparator.